表紙:T細胞療法市場:療法タイプ別、適応症別、エンドユーザー別:世界の機会分析と産業予測、2023-2032年
市場調査レポート
商品コード
1344541

T細胞療法市場:療法タイプ別、適応症別、エンドユーザー別:世界の機会分析と産業予測、2023-2032年

T-Cell therapy Market By Therapy Type (CAR T-Cell therapy, T-Cell Receptor -Based), By Indication, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: | 発行: Allied Market Research | ページ情報: 英文 274 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
T細胞療法市場:療法タイプ別、適応症別、エンドユーザー別:世界の機会分析と産業予測、2023-2032年
出版日: 2023年05月30日
発行: Allied Market Research
ページ情報: 英文 274 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Allied Market Researchが発行した最新レポートによると、T細胞療法市場は2022年に28億米ドルと評価され、2023年から2032年にかけてCAGR 18.3%で成長し、2032年には152億米ドルに達すると推定されています。

T細胞療法市場は、ロックダウン期間中に世界的なサプライチェーンの混乱により悪影響を受け、T細胞療法の生産と流通に影響を及ぼしました。さらに、COVID-19後のがんの蔓延は、医療分野におけるイノベーションの必要性を浮き彫りにしており、市場の成長にプラスの影響を与えていることが示されています。

T-Cell therapy Market-IMG1

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競合の激しさ
  • 市場力学
    • 促進要因
      • がんの有病率の上昇
      • 理想的な治療薬に対する需要の増加
      • T細胞療法に対する意識の高まり
    • 抑制要因
      • T細胞療法にかかるコストの高さ
      • 医薬品の承認に関する政府の厳しい規制
    • 機会
      • T細胞療法薬開発のための研究開発活動の増加
  • COVID-19:市場への影響分析

第4章 T細胞療法市場:療法タイプ別

  • 概要
  • CAR-T細胞療法
  • T細胞受容体(TCR)ベース

第5章 T細胞療法市場:適応症別

  • 概要
  • リンパ腫
  • 急性リンパ性白血病(ALL)
  • その他

第6章 T細胞療法市場:エンドユーザー別

  • 概要
  • 病院
  • がん治療センター

第7章 T細胞療法市場:地域別

  • 概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • その他欧州
  • アジア太平洋
    • 日本
    • 中国
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ラテンアメリカ
    • 中東・アフリカ

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2022年

第9章 企業プロファイル

  • Novartis AG
  • Autolus Therapeutics
  • Caribou Biosciences, Inc
  • Gilead Sciences, Inc.
  • Immunocore Ltd.
  • Celyad Oncology
  • Cartesian Therapeutics, Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Cellectis, Inc.
図表

LIST OF TABLES

  • TABLE 01. GLOBAL T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 02. T-CELL THERAPY MARKET FOR CAR T-CELL THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL CAR T-CELL THERAPY T-CELL THERAPY MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 04. T-CELL THERAPY MARKET FOR T-CELL RECEPTOR (TCR)-BASED, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 06. T-CELL THERAPY MARKET FOR LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. T-CELL THERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. T-CELL THERAPY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 10. T-CELL THERAPY MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. T-CELL THERAPY MARKET FOR CANCER TREATMENT CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. T-CELL THERAPY MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA T-CELL THERAPY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 17. U.S. T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 18. U.S. T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 19. U.S. T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. CANADA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 21. CANADA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 22. CANADA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. EUROPE T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. EUROPE T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 25. EUROPE T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE T-CELL THERAPY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 27. GERMANY T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. GERMANY T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 29. GERMANY T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. FRANCE T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 31. FRANCE T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 32. FRANCE T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. UK T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. UK T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 35. UK T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. REST OF EUROPE T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. REST OF EUROPE T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 38. REST OF EUROPE T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. ASIA-PACIFIC T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 40. ASIA-PACIFIC T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 41. ASIA-PACIFIC T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. ASIA-PACIFIC T-CELL THERAPY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 43. JAPAN T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 44. JAPAN T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 45. JAPAN T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. CHINA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 47. CHINA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 48. CHINA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. REST OF ASIA-PACIFIC T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 50. REST OF ASIA-PACIFIC T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 51. REST OF ASIA-PACIFIC T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. LAMEA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 53. LAMEA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 54. LAMEA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. LAMEA T-CELL THERAPY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 56. LATIN AMERICA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 57. LATIN AMERICA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 58. LATIN AMERICA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. MIDDLE EAST AND AFRICA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 60. MIDDLE EAST AND AFRICA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 61. MIDDLE EAST AND AFRICA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 63. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 64. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 65. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 66. AUTOLUS THERAPEUTICS: KEY EXECUTIVES
  • TABLE 67. AUTOLUS THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 68. AUTOLUS THERAPEUTICS: PRODUCT SEGMENTS
  • TABLE 69. AUTOLUS THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 70. AUTOLUS THERAPEUTICS: KEY STRATERGIES
  • TABLE 71. CARIBOU BIOSCIENCES, INC: KEY EXECUTIVES
  • TABLE 72. CARIBOU BIOSCIENCES, INC: COMPANY SNAPSHOT
  • TABLE 73. CARIBOU BIOSCIENCES, INC: PRODUCT SEGMENTS
  • TABLE 74. CARIBOU BIOSCIENCES, INC: PRODUCT PORTFOLIO
  • TABLE 75. CARIBOU BIOSCIENCES, INC: KEY STRATERGIES
  • TABLE 76. GILEAD SCIENCES, INC.: KEY EXECUTIVES
  • TABLE 77. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 78. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
  • TABLE 79. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 80. GILEAD SCIENCES, INC.: KEY STRATERGIES
  • TABLE 81. IMMUNOCORE LTD.: KEY EXECUTIVES
  • TABLE 82. IMMUNOCORE LTD.: COMPANY SNAPSHOT
  • TABLE 83. IMMUNOCORE LTD.: PRODUCT SEGMENTS
  • TABLE 84. IMMUNOCORE LTD.: PRODUCT PORTFOLIO
  • TABLE 85. IMMUNOCORE LTD.: KEY STRATERGIES
  • TABLE 86. CELYAD ONCOLOGY: KEY EXECUTIVES
  • TABLE 87. CELYAD ONCOLOGY: COMPANY SNAPSHOT
  • TABLE 88. CELYAD ONCOLOGY: PRODUCT SEGMENTS
  • TABLE 89. CELYAD ONCOLOGY: PRODUCT PORTFOLIO
  • TABLE 90. CELYAD ONCOLOGY: KEY STRATERGIES
  • TABLE 91. CARTESIAN THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 92. CARTESIAN THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 93. CARTESIAN THERAPEUTICS, INC.: PRODUCT SEGMENTS
  • TABLE 94. CARTESIAN THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 95. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 96. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 97. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 98. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 99. JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 100. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 101. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 102. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
  • TABLE 103. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 104. CELLECTIS, INC.: KEY EXECUTIVES
  • TABLE 105. CELLECTIS, INC.: COMPANY SNAPSHOT
  • TABLE 106. CELLECTIS, INC.: PRODUCT SEGMENTS
  • TABLE 107. CELLECTIS, INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. T-CELL THERAPY MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF T-CELL THERAPY MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN T-CELL THERAPY MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALT-CELL THERAPY MARKET
  • FIGURE 10. T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF T-CELL THERAPY MARKET FOR CAR T-CELL THERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF T-CELL THERAPY MARKET FOR T-CELL RECEPTOR (TCR)-BASED, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. T-CELL THERAPY MARKET, BY INDICATION, 2022(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF T-CELL THERAPY MARKET FOR LYMPHOMA, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF T-CELL THERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF T-CELL THERAPY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. T-CELL THERAPY MARKET, BY END USER, 2022(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF T-CELL THERAPY MARKET FOR CANCER TREATMENT CENTERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. T-CELL THERAPY MARKET BY REGION, 2022
  • FIGURE 21. U.S. T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. CANADA T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. GERMANY T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. FRANCE T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. UK T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. REST OF EUROPE T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. JAPAN T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. CHINA T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. REST OF ASIA-PACIFIC T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. LATIN AMERICA T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. MIDDLE EAST AND AFRICA T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 33. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 34. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 35. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 36. COMPETITIVE DASHBOARD
  • FIGURE 37. COMPETITIVE HEATMAP: T-CELL THERAPY MARKET
  • FIGURE 38. TOP PLAYER POSITIONING, 2022
  • FIGURE 39. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 41. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 42. AUTOLUS THERAPEUTICS: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 43. CARIBOU BIOSCIENCES, INC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 44. CARIBOU BIOSCIENCES, INC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 45. GILEAD SCIENCES, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 46. GILEAD SCIENCES, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 47. IMMUNOCORE LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 48. IMMUNOCORE LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 49. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 51. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 52. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. CELLECTIS, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 55. CELLECTIS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
目次
Product Code: A10528

According to a new report published by Allied Market Research, titled, "T-Cell therapy Market," The t-cell therapy market was valued at $2.8 billion in 2022, and is estimated to reach $15.2 billion by 2032, growing at a CAGR of 18.3% from 2023 to 2032.

The T-Cell therapy market was negatively impacted during the lockdown period owing to a disrupted global supply chain, which had affected the production and distribution of T-cell therapies. Moreover, post COVID-19 prevailing cases of cancer has highlighted the need for innovation in the healthcare sector and thus shown positive impact on the growth of the market.

T-Cell therapy Market - IMG1

Market dynamics

The rise in cancer prevalence, rise in geriatric population, and rise in the use of various cell therapy technologies to treat the symptoms of cancer are the main drivers propelling the growth of the T-cell therapy market size. Leukemia, myeloma, lymphoma, and cancer relapse are among the cancers that are becoming more common, which increases the demand for effective therapeutic treatments and propels the market's expansion. For instance, according to National Library of Medicine in China 2022, is estimated the approximately 88,249 new cases of leukemia (50,213 male cases and 38,036 female cases). In addition, increase in number of clinical trials and increase in public and private investments for the development of cell therapy technology in which T cells are collected from a patient are genetically modified ex vivo and re-injected into the patient drive the T-cell therapy market growth.

Moreover, the T-cell therapy market is characterized by continuous evolution and growth, primarily fueled by ongoing research and development efforts. The field of T-cell therapy is dynamic, with scientists and researchers exploring novel approaches, technologies, and therapeutic targets to enhance the effectiveness and broaden the applications of T-cell therapies.

In addition, the presence of multiple drugs in the clinical development phase is also driving the market growth. For instance, CB-010 and CB-011 of Caribou Biosciences, Inc are in clinical phase I trials. Similarly, DESCARTES-17 and DESCARTES-25 of Cartesian Therapeutics, Inc. are in preclinical and Phase I trials respectively. Thus, the focus of key players on developments is further anticipated to potentially drive the growth during T-cell therapy market forecast.

Furthermore, the growing demand for effective therapeutic solutions is not only limited to developed countries but is also being witnessed in the developing countries, such as China, Brazil, and India, which fuel the growth of the market. Moreover, an increase in promotional activities by manufacturers and growth in awareness for proper treatment medications for cancer among the general population are expected to fuel their adoption during the forecast period.

However, the market growth of T-cell therapy is hindered by several factors including the high cost associated with T-cell therapy. It poses a barrier to its widespread adoption and limiting patient access. Furthermore, stringent government regulations and lengthy approval processes create delays in introducing T-cell therapies to the market, affecting their availability. In addition, the guidelines that restrict the use of T-cell therapy as a later line of treatment after chemotherapy failure limit its potential impact and delay its application in earlier stages of disease. These factors collectively impede the market growth of T-cell therapy, necessitating efforts to address cost concerns, streamline regulatory processes, and explore its utilization in earlier treatment settings.

The outbreak of COVID-19 has disrupted workflows in the health care sector around the world including the T-cell therapy market. The T-cell therapy market is negatively impacted by the pandemic as most countries adopted lockdown. Some companies experienced delays in the manufacture and delivery of T-cell therapies due to supply chain disruptions.

Additionally, many clinical trials of T-cell therapies had been disrupted due to the COVID-19 pandemic, with some trials being delayed or suspended altogether. This has slowed down the development and approval of new T-cell therapies. For instance, according to a Cancer Research Institute and IQVIA survey published in Nature Reviews Drug Discovery, found that patient enrollment in oncology clinical trials during the early stages of the pandemic was significantly impacted in the U.S and Europe, where 60% and 86% of institutions respectively were enrolling new patients at a lower rate. The main obstacles to enrollment in trials were access, concerns over patients' risk of contracting the virus. Thus, decline in people transit, closing of borders, and confinement of the population impacted the supply chains of these life-saving medical therapies and had a negative impact on the growth of T-cell therapy industry.

However, post pandemic it was observed that the prevailing cases of cancer have highlighted the need for innovation in the healthcare sector, and many companies are increasing their investments in research and development. Furthermore, the increasing approvals by regulatory agencies have further driven the opportunity for the key players. For instance, in November 2022, Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, received clearance for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-011, a genome-edited allogeneic anti-BCMA CAR-T cell therapy with immune cloaking. Thus, the increasing cases, growing demand for ideal therapeutics, and presence of multiple promising drugs in pipeline are expected to drive the market during the forecast years.

Segmental Overview

The global T-cell therapy market is segmented into therapy type, indication, end user and region. As per therapy type, the market is categorized into CAR T-cell Therapy and T Cell Receptor (TCR)-Based. The CAR T-cell Therapy segment is further categorized by product type into Axicabtagene Ciloleucel, Tisagenlecleucel, Bexucabtagene Autoleucel and Others (Ciltacabtagene autoleucel, Lisocabtagene Maraleucel, Idecabtagene Vicleucel). According to indication, the market is segregated into Lymphoma, Acute Lymphocytic Leukemia, and Others (Multiple Myeloma, Melanoma). According to end user, the market is segregated into Hospitals and Cancer Treatment Centers. Region wise, the market is analyzed across North America (the U.S., Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China and rest of Asia-Pacific), and LAMEA (Latin America, Middle East & Africa).

Key Benefits For Stakeholders:

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the t-cell therapy market analysis from 2022 to 2032 to identify the prevailing t-cell therapy market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the t-cell therapy market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global t-cell therapy market trends, key players, market segments, application areas, and market growth strategies.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of cancer
      • 3.4.1.2. Increase in demand of ideal therapeutics for treatment
      • 3.4.1.3. Rise in awareness regarding T-cell therapy
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of T-cell therapies
      • 3.4.2.2. Strict government regulation for approval of drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in R&D activities to develop T-cell therapeutics
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: T-CELL THERAPY MARKET, BY THERAPY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. CAR T-Cell therapy
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. CAR T-Cell therapy T-Cell therapy Market by Product Type
  • 4.3. T-Cell Receptor (TCR)-Based
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: T-CELL THERAPY MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Lymphoma
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Acute Lymphocytic Leukemia
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: T-CELL THERAPY MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Cancer Treatment Centers
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: T-CELL THERAPY MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Therapy Type
    • 7.2.3. Market size and forecast, by Indication
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Therapy Type
      • 7.2.5.1.3. Market size and forecast, by Indication
      • 7.2.5.1.4. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Therapy Type
      • 7.2.5.2.3. Market size and forecast, by Indication
      • 7.2.5.2.4. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Therapy Type
    • 7.3.3. Market size and forecast, by Indication
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Therapy Type
      • 7.3.5.1.3. Market size and forecast, by Indication
      • 7.3.5.1.4. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Therapy Type
      • 7.3.5.2.3. Market size and forecast, by Indication
      • 7.3.5.2.4. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Therapy Type
      • 7.3.5.3.3. Market size and forecast, by Indication
      • 7.3.5.3.4. Market size and forecast, by End User
      • 7.3.5.4. Rest of Europe
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Therapy Type
      • 7.3.5.4.3. Market size and forecast, by Indication
      • 7.3.5.4.4. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Therapy Type
    • 7.4.3. Market size and forecast, by Indication
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Therapy Type
      • 7.4.5.1.3. Market size and forecast, by Indication
      • 7.4.5.1.4. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Therapy Type
      • 7.4.5.2.3. Market size and forecast, by Indication
      • 7.4.5.2.4. Market size and forecast, by End User
      • 7.4.5.3. Rest of Asia-Pacific
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Therapy Type
      • 7.4.5.3.3. Market size and forecast, by Indication
      • 7.4.5.3.4. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Therapy Type
    • 7.5.3. Market size and forecast, by Indication
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Latin America
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Therapy Type
      • 7.5.5.1.3. Market size and forecast, by Indication
      • 7.5.5.1.4. Market size and forecast, by End User
      • 7.5.5.2. Middle East And Africa
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Therapy Type
      • 7.5.5.2.3. Market size and forecast, by Indication
      • 7.5.5.2.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Novartis AG
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Autolus Therapeutics
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Caribou Biosciences, Inc
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Gilead Sciences, Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Immunocore Ltd.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Celyad Oncology
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Key strategic moves and developments
  • 9.7. Cartesian Therapeutics, Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
  • 9.8. Johnson & Johnson
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Bristol-Myers Squibb Company
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Cellectis, Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance